Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07219368 · ClinicalTrials.gov registry record · Phase 1
A First-in-Human Single and Multiple Ascending Dose Study of MT-201
A Phase 1 study of Healthy Volunteer, sponsored by Mirador Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
- 1
- Study location
NCT07219368 is a Phase 1 study of Healthy Volunteer that is actively recruiting participants, run by Mirador Therapeutics. The registered enrollment target is 72 participants, below the 201-participant average among 112 other Healthy Volunteer trials with a reported enrollment target (64% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07219368, a Phase 1 study of Healthy Volunteer, is actively recruiting participants, sponsored by Mirador Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
- 1
- Study location
Study Summary
First-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of single and multiple doses of MT-201 in healthy participants.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG MT-201
Study Locations (1)
California
- Mirador Clinical Department, San Diego, California 92121 - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2025-10-08 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07219368
The ClinicalTrials.gov registry entry for NCT07219368 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 201-participant average among 112 other Healthy Volunteer trials with a reported enrollment target (64% lower). The listed sponsor is Mirador Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy Volunteer appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07219368 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT07219368 about?
NCT07219368 is a clinical study titled "A First-in-Human Single and Multiple Ascending Dose Study of MT-201". First-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of single and multiple doses of MT-201 in healthy participants.
What is the current status of trial NCT07219368?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2025-10-08. Estimated completion is 2026-12-31.
What conditions does trial NCT07219368 study?
This clinical trial studies the following conditions: Healthy Volunteer.
What interventions are being tested in trial NCT07219368?
The interventions under investigation include: Placebo (DRUG), MT-201 (DRUG).
Who is sponsoring clinical trial NCT07219368?
This trial is sponsored by Mirador Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07219368 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Volunteer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Healthy Volunteer Study
RECRUITING · Phase 1
-
Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder
RECRUITING · Phase 1
-
Role of Metal Ion Transporter ZIP8 in Alcohol-Related Behaviors
RECRUITING · Phase 1
-
A Study to Assess the Adverse Events and How Oral Emraclidine Moves Through the Body of Healthy Elderly Adult Participants
RECRUITING · Phase 1
-
A Study to Assess How the Drug Moves Through the Body, Adverse Events, and Tolerability of Oral ABBV-722 Capsules of Single and Multiple Ascending Doses in Adult Participants and Single Doses in Adult Asian Participants
RECRUITING · Phase 1
-
Safety and Immunogenicity of Ad4-HIV Envelope Vaccine Vectors in Healthy Volunteers
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.